Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease

At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel urgencyMirikizumab also helped over 50% of patients with moderately to severely active Crohn's disease sustain long-term endoscopic remission for up to five years INDIANAPOLIS, Oct. 28, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from two, multi-year, Phase 3 studies that showed patien ...